



March 13, 2012

NeuroMetrix Announces Warrant Redemption

WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 13, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes, today announced plans to redeem warrants to purchase an aggregate of 1,430,480 shares of common stock, par value \$0.0001 per share, that were issued in connection with a NeuroMetrix securities offering in September 2009. The warrants will be redeemed in exchange for 138,763 shares of common stock.

The warrant redemption will satisfy an obligation of the Company under Securities Purchase Agreements dated September 8, 2009, as amended. The Company will issue the shares under a prospectus supplement dated March 12, 2012 and an accompanying prospectus dated April 16, 2010, pursuant to the Company's shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission on April 14, 2010. Following the warrant redemption, NeuroMetrix will have approximately 12.6 million shares of common stock outstanding.

About NeuroMetrix

NeuroMetrix is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company currently markets products for the detection, diagnosis, and monitoring of diabetic neuropathies such as diabetic peripheral neuropathy and median neuropathy (carpal tunnel syndrome). For more information, please visit <http://www.neurometrix.com>.

Source: NeuroMetrix, Inc.

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief Financial Officer
neurometrix.ir@neurometrix.com